110.86

0.24% 0.6413

Ligand Pharmaceuticals Inc (LGND)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Ligand Pharmaceuticals Inc stock is traded at $110.86, with a volume of 31,011. It is up +0.24% in the last 24 hours and up +5.44% over the past month.

Previous Close:

$110.22

Open:

$109.57

24h Volume:

31,011

Relative Volume:

0.31

Market Cap:

$1.82B

Revenue:

$118.31M

Net Income/Loss:

$96.34M

P/E Ratio:

76.99

EPS:

1.44

Net Cash Flow:

$-19.62M

1W Performance:

-4.37%

1M Performance:

+5.44%

6M Performance:

+49.51%

1Y Performance:

+104.64%

1-Day Range:

$108.31

$110.58

1-Week Range:

$105.47

$115.10

52-Week Range:

$51.21

$115.53

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name

Ligand Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-550-7500

Address

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Employee

Twitter

@Ligand_LGND

Next Earnings Date

2024-11-07

Latest SEC Filings

LGND's Discussions on Twitter

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-21	Resumed	Stephens	Overweight
Feb-04-21	Reiterated	H.C. Wainwright	Buy
Oct-06-20	Initiated	Barclays	Overweight
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-03-19	Reiterated	H.C. Wainwright	Buy
Mar-06-19	Reiterated	H.C. Wainwright	Buy
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-11-18	Reiterated	Argus	Buy
Aug-17-18	Initiated	Goldman	Neutral
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy
Dec-27-17	Reiterated	H.C. Wainwright	Buy
Sep-05-17	Resumed	H.C. Wainwright	Buy
Oct-05-16	Reiterated	H.C. Wainwright	Buy
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell
Mar-11-16	Initiated	Sidoti	Buy
Mar-03-16	Initiated	H.C. Wainwright	Buy

View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

Nov 04, 2024

H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow

Nov 04, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from HC Wainwright - Defense World

Nov 04, 2024

Nov 01, 2024

Macquarie Group Ltd's Strategic Reduction in Ligand Pharmaceuticals Inc - GuruFocus.com

Nov 01, 2024

Ligand Pharmaceuticals (STU:LGDN) Preferred Stock : €0.0 Mil (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024

Ligand Pharmaceuticals (FRA:LGDN) Momentum Rank : 6 (As of Nov. 01, 2024) - GuruFocus.com

Nov 01, 2024

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston - StockTitan

Nov 01, 2024

abrdn plc Has $24.95 Million Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings - Simply Wall St

Oct 31, 2024

Congress Asset Management Co. Has $60.46 Million Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Oct 31, 2024

Ligand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 31, 2024

Oct 28, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Oct 28, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $125.00 - MarketBeat

Oct 28, 2024

Oct 26, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Raised by Allspring Global Investments Holdings LLC - MarketBeat

Oct 26, 2024

Oct 25, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighTime to Buy? - MarketBeat

Oct 25, 2024

Ligand Pharmaceuticals stock hits 52-week high at $112.25 - Investing.com

Oct 25, 2024

Oct 23, 2024

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 - Marketscreener.com

Oct 23, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00 at HC Wainwright - Defense World

Oct 23, 2024

Oct 21, 2024

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga

Oct 21, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00 - MarketBeat

Oct 21, 2024

Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts - Benzinga

Oct 21, 2024

Oct 20, 2024

Chicago Capital LLC Has $54.63 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Oct 20, 2024

Oct 17, 2024

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

AQR Capital Management LLC Cuts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Oct 16, 2024

Oct 14, 2024

Double Barreled Antibodies Drug Market In-Depth Analysis, Business Forecast and Dynamics 2023 – (2024-2034) - IndiaPolitics.com

Oct 14, 2024

Oct 09, 2024